Kim MH, Lee SS, Lee SK, Lee SG, Suh CW, Gong GY, Park JS, Kim YH, Kim SH. Interleukin-2 gene-encoded stromal cells inhibit the growth of metastatic cholangiocarcinomas. World J Gastroenterol 2006; 12(12): 1889-1894 [PMID: 16609995 DOI: 10.3748/wjg.v12.i12.1889]
Corresponding Author of This Article
Dr. Sang-Hee Kim, Asan Institute for Life Sciences, 388-1 Poongnapdong, Songpagu, Seoul 138-736, South Korea. sbkcdh@comcast.net
Article-Type of This Article
Basic Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 28, 2006; 12(12): 1889-1894 Published online Mar 28, 2006. doi: 10.3748/wjg.v12.i12.1889
Interleukin-2 gene-encoded stromal cells inhibit the growth of metastatic cholangiocarcinomas
Myung-Hwan Kim, Sang Soo Lee, Sung Koo Lee, Seung-Gyu Lee, Chul-Won Suh, Gyung-Yub Gong, Jung-Sun Park, Young-Hoon Kim, Sang-Hee Kim
Myung-Hwan Kim, Sang Soo Lee, Sung Koo Lee, Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Seung-Gyu Lee, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Chul-Won Suh, Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Gyung-Yub Gong, Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Jung-Sun Park, Young-Hoon Kim, Sang-Hee Kim, Asan Institute for Life Sciences, Seoul, Korea
Co-first-authors: Myung-Hwan Kim
Supported by The Asan Institute for Life Sciences of South Korea, No. 2003-013
Correspondence to: Dr. Sang-Hee Kim, Asan Institute for Life Sciences, 388-1 Poongnapdong, Songpagu, Seoul 138-736, South Korea. sbkcdh@comcast.net
Telephone: +82-2-30104175 Fax: +82-2-30104182
Received: August 23, 2005 Revised: October 2, 2005 Accepted: October 9, 2005 Published online: March 28, 2006
Abstract
AIM: To demonstrate bone marrow stromal cells (BMSCs) can be used as an attractive target for genetic modification in the treatment of malignant diseases.
METHODS: Using a hamster model of biliary cancer, we investigated the therapeutic effects of interleukin-2 (IL-2) gene-modified BMSCs. Syrian golden hamsters were injected via the femoral vein with 5×105 cells of the KIGB-5 biliary cancer cell line (n=20). One week later, the hamsters were injected intraperitoneally with BMSCs containing Ad/hIL-2 and Ad/ΔE1, unmodified BMSCs, or RPMI only (control) and observed for 12 wk (n=5 /each group).
RESULTS: All hamsters treated with BMSCs containing Ad/hIL-2 survived with no evidence of the disease during this period. In contrast, hamsters in the other three groups showed disseminated metastases involving the lungs as early as 4 wk.
CONCLUSION: Ad/IL-2 therapy is effective in the treatment of biliary cancer.
